S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
NASDAQ:NVCN

Neovasc (NVCN) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$29.43
$30.07
50-Day Range
$29.03
$30.03
52-Week Range
$4.59
$30.07
Volume
45,400 shs
Average Volume
56,993 shs
Market Capitalization
$82.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NVCN stock logo

About Neovasc (NASDAQ:NVCN) Stock

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

Receive NVCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neovasc and its competitors with MarketBeat's FREE daily newsletter.

NVCN Stock News Headlines

Neovasc (NASDAQ:NVCN) Now Covered by StockNews.com
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
Closing Bell: Neovasc Inc down on Tuesday (NVCN)
Neovasc (NASDAQ:NVCN) Now Covered by Analysts at StockNews.com
Closing Bell: Neovasc Inc up on Monday (NVCN)
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
StockNews.com Begins Coverage on Neovasc (NASDAQ:NVCN)
Neovasc Announces German Reimbursement Renewal
Neovasc Announces Progress on COSIRA-II Clinical Trial
Neovasc Third Quarter 2022 Earnings: Misses Expectations
Form 6-K NEOVASC INC For: Sep 20 - StreetInsider.com
See More Headlines

Receive NVCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neovasc and its competitors with MarketBeat's FREE daily newsletter.

NVCN Company Calendar

Last Earnings
3/31/2023
Today
5/31/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVCN
Employees
49
Year Founded
N/A

Profitability

Net Income
$-41,200,000.00
Net Margins
-1,082.92%
Pretax Margin
-1,082.26%

Debt

Sales & Book Value

Annual Sales
$3.81 million
Book Value
$5.77 per share

Miscellaneous

Free Float
N/A
Market Cap
$82.28 million
Optionable
Not Optionable
Beta
1.70

Key Executives

  • Fredericus Antonius Colen
    President, Chief Executive Officer & Director
  • Bill Little
    Chief Operating Officer
  • Christopher Clark
    Chief Financial Officer & Secretary
  • Sarah Gallagher
    Vice President-Clinical Affairs
  • Shmuel Banai
    Medical Director













NVCN Stock - Frequently Asked Questions

Should I buy or sell Neovasc stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVCN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCN, but not buy additional shares or sell existing shares.
View NVCN analyst ratings
or view top-rated stocks.

How were Neovasc's earnings last quarter?

Neovasc Inc. (NASDAQ:NVCN) announced its earnings results on Friday, March, 31st. The medical equipment provider reported ($5.04) earnings per share for the quarter, missing the consensus estimate of ($1.93) by $3.11. The medical equipment provider had revenue of $1.45 million for the quarter, compared to analyst estimates of $0.90 million. Neovasc had a negative trailing twelve-month return on equity of 127.25% and a negative net margin of 1,082.92%.

When did Neovasc's stock split?

Neovasc's stock reverse split on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Neovasc own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Heat Biologics (HTBX), Protalix BioTherapeutics (PLX), Palatin Technologies (PTN), Amarin (AMRN).

What is Neovasc's stock symbol?

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Who are Neovasc's major shareholders?

Neovasc's stock is owned by many different retail and institutional investors. Top institutional shareholders include Black Maple Capital Management LP (3.93%), Yakira Capital Management Inc. (1.37%), MMCAP International Inc. SPC (1.01%), Sio Capital Management LLC (0.82%), Quinn Opportunity Partners LLC (0.73%) and Renaissance Technologies LLC (0.64%).

What is Neovasc's stock price today?

One share of NVCN stock can currently be purchased for approximately $30.03.

How much money does Neovasc make?

Neovasc (NASDAQ:NVCN) has a market capitalization of $82.28 million and generates $3.81 million in revenue each year. The medical equipment provider earns $-41,200,000.00 in net income (profit) each year or ($15.08) on an earnings per share basis.

How can I contact Neovasc?

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The official website for the company is www.neovasc.com. The medical equipment provider can be reached via phone at (604) 270-4344, via email at investors@neovasc.com, or via fax at 604-270-4384.

This page (NASDAQ:NVCN) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -